Protocol Ledger

NCT05007951 · Phase III · COMPLETED

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Interventional Phase III clinical trial protocol NCT05007951 sponsored by SK Bioscience Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-30 Enrollment: 4,036 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05007951
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,036 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05007951
Protocol FieldVerified Registry Value
NCT IdentifierNCT05007951
Consolidated Lead SponsorSK Bioscience Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment4,036 participants (ACTUAL)
Registered Start Date2021-08-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05007951
Hospital Research SiteLocationSite Profile
Ajou University HospitalSuwon, South KoreaOpen Hospital Dossier ->
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Kyungpook National University Chilgok HospitalDaegu, South KoreaOpen Hospital Dossier ->
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI